课题基金 / 基金详情

NEW TRITERPENOIDS FROM INDIAN PLANTS TO PREVENT CANCER

NEW TRITERPENOIDS FROM INDIAN PLANTS TO PREVENT CANCER
来自印度植物的新三萜类化合物可预防癌症
批准号:
6132703
负责人:
Michael B Sporn
金额:
$4.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2003-06-30

项目摘要

项目成果

Michael B Sporn的其他基金

相似基金

相关文献

中文摘要
翻译
NIH Grant R 01 CA 78814 - 01 A1的主要目标是开发新的化学试剂,称为三萜类化合物,用于癌症的化学预防。 对预防癌症的新药剂的需要从常见形式的癌症的持续的世界范围的高死亡率显而易见。 在达特茅斯医学院药理学系和达特茅斯学院化学系的共同努力下,我们已经在这方面取得了很大的进展。 到目前为止,该项目涉及分子和细胞生物学家以及有机化学家的共同努力。 研究策略是化学家合成新的三萜类化合物,然后生物学家评估这些新化合物的有用药理活性。 我们现在希望在高度相关的国际合作中推广同样的方法,其中包括位于印度班加罗尔的世界著名印度科学研究所的熟练生物学家和化学家。 拟议的合作是以达特茅斯项目为蓝本的。 主要需要用于药物开发的新的三萜类化合物结构。 达特茅斯项目在获取三萜类化合物方面受到限制,三萜类化合物作为天然产物存在于亚洲广泛存在的植物中。 班加罗尔科学研究所的化学系有一个杰出的出版记录,分离和表征了许多在印度本土植物中发现的三萜类化合物。 这些药物将在班加罗尔用于两个目的:1)它们将作为潜在的药理学药物进行测试; 2)它们将作为合成新药的起点,这些新药将在本计划中进行测试,其方式与达特茅斯计划类似。此外,班加罗尔研究所的分子生殖、发育和遗传学系在基础分子和细胞生物学方面有着出色的技能,该系的研究人员也将以类似于达特茅斯计划的方式在该项目的生物学方面进行合作。 这个拟议项目的基本特点将是班加罗尔和达特茅斯的调查人员之间密切合作和交换信息和材料。 将在班加罗尔进行的化学和生物学的性质将是这样的,它将扩大和加强达特茅斯计划的努力,而不会重复或重叠。
英文摘要
The primary goal of NIH Grant R01 CA78814-01A1 is to develop new chemical agents, called triterpenoids, for the chemoprevention of cancer. The need for new agents to prevent cancer is readily evident from the continuing worldwide high mortality rates for the common forms of cancer. In a collaborative effort between the Department of Pharmacology, Dartmouth Medical School, and the Department of Chemistry, Dartmouth College, we have already made excellent progress toward this. The project thus far has involved the joint efforts of molecular and cell biologists and organic chemists. The research strategy has been for the chemists to synthesize new triterpenoids, and then for the biologists to evaluate these new compounds for useful pharmacological activity. We now wish to extend this same approach in a highly related international collaboration, involving skilled biologists and chemists at the world-renowned Indian Institute of Science, in Bangalore, India. The proposed collaboration is modelled on the Dartmouth project. There is a major need for new triterpenoid structures to be used for drug development. The Dartmouth project is limited in its access to triterpenoids that occur as natural products in plants that are found widely in Asia. The Department of Chemistry at the Institute of Science in Bangalore has a distinguished publication record of isolating and characterizing many triterpenoids found in native Indian plants. Such agents will be used in Bangalore for two purposes: 1) they will be tested themselves as potential pharmacological agents; and 2) they will be used as a starting point for the synthesis of new drugs that will be tested in this program, in a manner similar to the Dartmouth program. Furthermore, there are excellent skills in basic molecular and cell biology in the Department of Molecular Reproduction, Development, and Genetics at the Institute in Bangalore, and investigators in that Department will also collaborate on the biological aspects of this project, again in a manner similar to the Dartmouth program. The essential feature of this proposed project will be a close collaboration and interchange of information and materials between the investigators in Bangalore and those at Dartmouth. The nature of the chemistry and biology that will be performed in Bangalore will be such that it will expand and enhance the efforts of the Dartmouth program, without duplicating or overlapping with it.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Glioblastoma
  • 批准号:
    10081123
  • 项目类别:
  • 资助金额:
    $39.99万
  • 财政年份:
    2020
  • 负责人:
    Michael B Sporn
  • 依托单位:
Development of the New Synthetic Triterpenoid CDDO-2P-Im for Chemoprevention of the ARDS of COVID-19
  • 批准号:
    10202843
  • 项目类别:
  • 资助金额:
    $24.98万
  • 财政年份:
    2020
  • 负责人:
    Michael B Sporn
  • 依托单位:
Conference on Roles of TGF-Beta in Disease Pathogenesis
  • 批准号:
    6887127
  • 项目类别:
  • 资助金额:
    $0.3万
  • 财政年份:
    2005
  • 负责人:
    Michael B Sporn
  • 依托单位:
Chemoprevention of Estrogen Receptor Negative Breast Cancer
  • 批准号:
    7236736
  • 项目类别:
  • 资助金额:
    $33.33万
  • 财政年份:
    2003
  • 负责人:
    Michael B Sporn
  • 依托单位:
海外基金